10062122The University of Leicester and Isogenica Limited KTP 22_23 R5ActiveKnowledge Transfer PartnershipInnovate UKTo develop a new to market drug validated in pre-clinical programmes ('virtual cancer patient') aimed at improving cancer immunotherapy.